188金宝搏网址信誉Omnicell完成了FDS Amplicare的收购

扩大零售药房客户的全国占地面积，将行业领先的财务管理，分析和人口健康解决方案添加到EliveNH188金宝搏ios下载ealth Division产品中

SaaS解决方案的添加加速了ElivenHealth的创新路线图，以帮助零售药店预测并减少DIR费用

预计将立即获得非GAAP EBITDA和非GAAP每股收益

188金宝搏网址信誉Omnicell，Inc。（NASDAQ：OMCL）是用于卫生系统和药房的药物管理解决方案和依从工具的领先提供商，今天宣布已完成先前宣布的FDS Amplicare的收购。此次收购为Omnicell的ElivenHealth™部门增加了SaaS财务管理，分析和人口健康解决方案的全面和互补的套件。188金宝搏网址信誉

EnlivenHealth是针对零售药房和健康计划的患者参与解决方案的行业领先的提供商。EnlivenHealth的使命是建立和协调高级数字解决方案，以帮助其客户可衡量的改善患者的健康状况，同时实现推动增长和盈利能力的新临床服务。188金宝搏ios下载FDS Amplicare的差异化财务管理，分析和人口健康解决方案以及其全国范围内拥有15,000多家独立零售药店的网络，扩大了EmanivenHealth的广泛行业足迹，同时补充了ElivenHealth的卫生服务和任务。

“The digitization of virtually every aspect of healthcare and the COVID-19 pandemic have accelerated fundamental shifts in how, where, and when care is delivered, with retail pharmacies at the forefront of these historic changes,” said Randall Lipps, chairman, president, CEO, and founder of Omnicell. “By combining EnlivenHealth’s strong patient engagement and clinical capabilities with FDS Amplicare’s widely deployed financial and analytics solutions, we are even better positioned to strengthen the health of our retail pharmacy and health plan customers and the patient populations they serve.”

Accelerates DIR Mitigation Solution Roadmap and Leadership

Direct & Indirect Remuneration (DIR) fees continue to challenge the business health of the retail pharmacy industry, especially independent pharmacies. FDS Amplicare’s industry-leading financial management, analytics, and Medicare plan selection solutions are important components that are helping retail pharmacies to manage, forecast, and mitigate their DIR fee exposure. Combined with EnlivenHealth’s proven clinical and data science capabilities, this differentiated, multi-pronged offering is designed to enable retail pharmacies to bend the DIR growth curve.

Under the terms of the purchase agreement, the acquisition price was $177 million, subject to customary adjustments. The FDS Amplicare business that is being acquired recorded approximately $29 million in total revenue (unaudited) for the 12 months ended June 30, 2021. Omnicell used available cash on its balance sheet to finance the transaction, which is expected to be immediately accretive to Omnicell’s non-GAAP EBITDA and non-GAAP Earnings per share.

“With the addition of these new capabilities, EnlivenHealth now offers the industry’s most comprehensive suite of digital technology solutions that are proven to help retail pharmacies and health plans grow and succeed in the new digital-driven era of healthcare,” said Scott Seidelmann, executive vice president and chief commercial officer, Omnicell. “We are thrilled to welcome our new colleagues from FDS Amplicare to the Omnicell/EnlivenHealth family. We look forward to working with them to advance our shared vision of being the most trusted partner for pharmacies and health plans to ensure the lifelong, optimal health of patients.”

Additional details of this acquisition are included in an investor presentation found in the投资者关系section of our website.

前瞻性语句

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the expected benefits of the acquisition of the FDS Amplicare business, including on Omnicell’s non-GAAP EBITDA and non-GAAP earnings per share, the impact of the acquisition on Omnicell’s products and services and the capabilities of the products and services of the FDS Amplicare business. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “plan,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seeks,” “predicts,” and “projects” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. There are a significant number of factors that involve substantial known and unknown risks and uncertainties, which could cause actual results to differ materially from statements made in this release, including, among other things: (i) difficulties encountered in integrating the acquired business, including technologies, personnel, and operations; (ii) costs related to the acquisition of FDS Amplicare; (iii) market acceptance of the acquisition of FDS Amplicare and resulting products and services; (iv) Omnicell’s inability to realize value from its significant investments in its business, including product and service innovations; (v) general market, political, economic, and business conditions, including the ongoing COVID-19 pandemic, and other industry or economic conditions outside of Omnicell’s control; and (vi) other risks and uncertainties described in Part I, Item 1A, “Risk Factors” in Omnicell’s Annual Report on Form 10-K for the year ended December 31, 2020, as updated in Omnicell’s subsequently filed Quarterly Reports on Form 10-Q, all of which are on file with the U.S. Securities and Exchange Commission (“SEC”), and in Omnicell’s other filings with the SEC. Forward-looking statements should be considered in light of these risks and uncertainties. Investors are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, new information, future events, or otherwise, except as required by law.

顾问

Evercore曾担任财务顾问，并向Omnicell和Sidley Austin LLP提供了公平的意见，曾担任Omnicell的法律顾问。188金宝搏网址信誉Baird曾担任FDS Amplicare的财务顾问，Willkie Farr＆Gallagher曾担任FDS Amplicare的法律顾问。